D-1386-2019 Class III Terminated
FDA drug recall D-1386-2019 was initiated by Fresenius Kabi USA, LLC on May 22, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is terminated (terminated Jan 28, 2021). Affected quantity: 11,981 units.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 19, 2019
- Initiation Date
- May 22, 2019
- Termination Date
- Jan 28, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 11,981 units
Product description
Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047, NDC 63323-374-20
Reason for recall
Failed Impurities/Degradation Specifications.
Distribution pattern
Nationwide within the United States
Code information
Lot #: 6018699, Exp. 12/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1386-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026